The pH-dependent degradation of peptides through pyroglutamate formation behaves differently in freeze-dried solids compared to liquid solutions, with faster degradation in solids at the pH range commonly used for antibody formulations.
Faster degradation in solids at pH 5.5-6The very pH range commonly used for monoclonal antibody formulations
What the researchers found
At pH 5.5-6 (the range commonly used for mAb formulations), pyroglutamate formation in lyophilized solids was faster than in solution, with markedly different pH-dependence profiles between the two states.
Why it matters
Understanding how peptide drugs degrade during storage is critical for developing stable formulations. The finding that freeze-drying doesn't always protect against degradation at common formulation pH values could change how pharmaceutical companies design peptide and antibody products.
The numbers in context
Strong pH dependence in solution and solid state; buffer species affected reaction rate; first detailed solid-state study.
How the study worked
Model peptide (EVQLVESGGGLVQPGGSLR) formulated at pH 4-9 in multiple buffer systems, lyophilized or kept in solution, stored at 50°C for 10+ weeks, with pGlu formation monitored by RP-HPLC.
Who was studied
Model peptide EVQLVESGGGLVQPGGSLR in various pH formulations
What this study cannot tell us
Used a single model peptide at accelerated storage conditions (50°C). Results may not directly translate to all peptides and proteins or real-world storage temperatures.
How to read the evidence
Well-controlled laboratory study with systematic pH comparisons across multiple buffer systems, providing strong mechanistic evidence for formulation science.
When this study was published
Published in 2021, reflecting current pharmaceutical formulation science and practices.
The bigger picture
Freeze-drying is widely used to stabilize peptide and protein drugs for storage. This study challenges the assumption that lyophilization always reduces chemical degradation, showing that the relationship between pH and stability is fundamentally different in solid versus liquid formulations. This has practical implications for the pharmaceutical industry's approach to formulation development.
Questions still open
- Do these findings apply to full-length monoclonal antibodies or other therapeutic peptides?
- What is the optimal pH for lyophilized peptide formulations to minimize pyroglutamate formation?
- How do different excipients affect the solid-state pH dependence of this reaction?
Common questions
What is pyroglutamate formation and why does it matter?
Why is it surprising that freeze-dried peptides degrade faster?
Read the original research
Effect of 'pH' on the Rate of Pyroglutamate Formation in Solution and Lyophilized Solids.
Molecular pharmaceutics, 18(8), 3116-3124
Citation
Bersin, Lia M; Patel, Sajal M; Topp, Elizabeth M. (2021). Effect of 'pH' on the Rate of Pyroglutamate Formation in Solution and Lyophilized Solids.. Molecular pharmaceutics, 18(8), 3116-3124. https://doi.org/10.1021/acs.molpharmaceut.1c00338